Big Pharma Continues Emerging Market Growth Trajectory
This article was originally published in PharmAsia News
While it may appear that the emerging markets have faded somewhat as the new darlings of big pharma, an analysis by Deutsche Bank of the latest financial performance of large European pharma companies suggests that they are still able to achieve a measure of growth in the region, just not as quickly as previously hoped.
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.